You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Fiber Pigtailed On-Chip Mid-infrared Difference Frequency Generation in Silicon
SBC: OMEGA OPTICS, INC. Topic: 90102Omega Optics will develop a fiber-coupled platform in strained silicon-on-sapphire (SoS) for tunable difference frequency generation in midwave infrared (MIR) with tunable continuous wave sources in the near-infrared (NIR). Stress exerted by silicon nitride on underlying silicon induces second-order nonlinear susceptibility. NIR light is coupled into silicon and MWIR light is coupled out of silico ...
SBIR Phase I 2016 Department of CommerceNational Institute of Standards and Technology -
Novel SCD1 inhibitors for treatment of cancer
SBC: MODULATION THERAPEUTICS, INC. Topic: 102DESCRIPTION provided by applicant Metastatic clear cell renal cell carcinoma mccRCC is an incurable cancer with a year survival of less than for which novel therapeutic agents need to be developed urgently It is notoriously resistant to chemotherapy and radiation Although molecularly targeted therapies have led to an improvement in survival the benefit is rather limited due to event ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
SBC: 7 Hills Pharma LLC Topic: 102DESCRIPTION provided by applicant Recent FDA approvals of ipilimumab nivolumab and pembrolizumab which target checkpoint receptors cytotoxic T lymphocyte associated antigen CTLA and programmed death PD have ushered in a new era of cancer immunotherapy in metastatic melanoma Despite unprecedented overall survival benefits with combination therapy the incidence of complete respo ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A cloud-based secure patient information exchange framework for managing treatment accessibility, utilization, quality, and outcomes in behavioral health clinics
SBC: Waldron International llc Topic: NIDADESCRIPTION In communities across the United States clinical populations exhibiting mental health and or substance abuse disorders face substantial challenges in accessing and receiving high quality and effective behavioral healthcare services Health Information technology HIT has been identified as an important component of improving access to behavioral healthcare in rural communities yet t ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
High-potency nitro antimicrobials for topical treatment of trichomoniasis
SBC: DESIGNMEDIX, INC. Topic: RDESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the world and million cases in the U S In addition to infections of the urogenital tract trichomoniasis increases the risk of adverse pregnancy outcomes and HIV transmission and increases the incidence ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin
SBC: Sano Chemicals, Inc. Topic: NIAIDDESCRIPTION provided by applicant Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have als ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: NIAIDDESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Clinical real-time resting state fMRI
SBC: NeurInsight, LLC Topic: 108DESCRIPTION provided by applicant Surgical resection of brain neoplasms aims at maximizing long term survival by gross total resection of tumor tissue while preserving the patientandapos s functional status Task based functional MRI fMRI is increasingly used as an adjunct to intra operative electrocorticography for mapping eloquent cortex but suffers a significant failure rate due to funct ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Blood based diagnostics for Alzheimer s Disease
SBC: Amprion, Inc. Topic: NIADESCRIPTION provided by applicant This proposal is for a phase I II fast track project for the STTR program with the main goal to develop a blood test for Alzheimerandapos s disease AD diagnosis AD is the most common dementia in the elderly population and one of the leading causes of death in the developed world One of the main problems in AD is the lack of an early sensitive and objective ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Digital Gene Expression Analysis by 3’ End Sequencing
SBC: BIOO SCIENTIFIC CORPORATION Topic: 172DESCRIPTION provided by applicant A key application of deep sequencing is gene expression analysis at the RNA level commonly known as RNA seq Reads from RNA seq cover all regions of an mRNA sequence However sequences derived from the andapos end region are sufficient to indicate gene expression levels All andapos end sequencing methods have revealed that most eukaryotic genes display a ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health